Dermatomyositis associated interstitial lung disease
Conditions
Interventions
None listed
Sponsors
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine,Kurume University School of Medicine
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine Department of Respirology, NHO Kyushu Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet criteria of dermatomyositis
Exclusion criteria
Exclusion criteria: 1, Patients who were determined inappropriate for this study 2, Patients who have other diseases other than interstitial lung disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detecting risk SNP for development of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Detecting risk SNP for development of ILD in anti-MDA5 antibody-positive dermatomyositis 2, Comparison of SNP frequency between anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease patients and disease control. 3. Study of association between disease associated SNP frequency and clinical data. 4. Study of association between disease associated SNP frequency and overall survival. | — |
Countries
Japan
Contacts
Public ContactMasaki Okamoto
Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine,
Outcome results
None listed